JP2015523072A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523072A5
JP2015523072A5 JP2015520567A JP2015520567A JP2015523072A5 JP 2015523072 A5 JP2015523072 A5 JP 2015523072A5 JP 2015520567 A JP2015520567 A JP 2015520567A JP 2015520567 A JP2015520567 A JP 2015520567A JP 2015523072 A5 JP2015523072 A5 JP 2015523072A5
Authority
JP
Japan
Prior art keywords
composition
purified recombinant
seq
conversion
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520567A
Other languages
English (en)
Japanese (ja)
Other versions
JP6171007B2 (ja
JP2015523072A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/048561 external-priority patent/WO2014005014A2/en
Publication of JP2015523072A publication Critical patent/JP2015523072A/ja
Publication of JP2015523072A5 publication Critical patent/JP2015523072A5/ja
Application granted granted Critical
Publication of JP6171007B2 publication Critical patent/JP6171007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520567A 2012-06-29 2013-06-28 組換えイズロン酸２スルファターゼの精製 Active JP6171007B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
US61/666,733 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016060910A Division JP6505629B2 (ja) 2012-06-29 2016-03-24 組換えイズロン酸２スルファターゼの精製

Publications (3)

Publication Number Publication Date
JP2015523072A JP2015523072A (ja) 2015-08-13
JP2015523072A5 true JP2015523072A5 (https=) 2016-01-07
JP6171007B2 JP6171007B2 (ja) 2017-07-26

Family

ID=49778401

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015520567A Active JP6171007B2 (ja) 2012-06-29 2013-06-28 組換えイズロン酸２スルファターゼの精製
JP2016060910A Active JP6505629B2 (ja) 2012-06-29 2016-03-24 組換えイズロン酸２スルファターゼの精製
JP2018067404A Withdrawn JP2018121645A (ja) 2012-06-29 2018-03-30 組換えイズロン酸２スルファターゼの精製
JP2020037811A Active JP7594365B2 (ja) 2012-06-29 2020-03-05 組換えイズロン酸２スルファターゼの精製

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016060910A Active JP6505629B2 (ja) 2012-06-29 2016-03-24 組換えイズロン酸２スルファターゼの精製
JP2018067404A Withdrawn JP2018121645A (ja) 2012-06-29 2018-03-30 組換えイズロン酸２スルファターゼの精製
JP2020037811A Active JP7594365B2 (ja) 2012-06-29 2020-03-05 組換えイズロン酸２スルファターゼの精製

Country Status (39)

Country Link
US (7) US9051556B2 (https=)
EP (2) EP3441398A1 (https=)
JP (4) JP6171007B2 (https=)
KR (5) KR101380740B1 (https=)
CN (3) CN107596357A (https=)
AR (1) AR091647A1 (https=)
AU (3) AU2013282395C1 (https=)
BR (1) BR112014032567B1 (https=)
CA (2) CA2877517C (https=)
CL (1) CL2014003567A1 (https=)
CO (1) CO7240396A2 (https=)
CR (1) CR20140588A (https=)
CY (1) CY1121519T1 (https=)
DK (1) DK2867245T3 (https=)
DO (1) DOP2014000294A (https=)
EA (2) EA034549B1 (https=)
ES (1) ES2689468T3 (https=)
GT (1) GT201400303A (https=)
HK (3) HK1209431A1 (https=)
HR (1) HRP20181897T1 (https=)
HU (1) HUE040769T2 (https=)
IL (4) IL236315A (https=)
LT (1) LT2867245T (https=)
MX (3) MX336715B (https=)
MY (3) MY157087A (https=)
NZ (3) NZ733366A (https=)
PE (1) PE20150720A1 (https=)
PH (3) PH12014502871B1 (https=)
PL (1) PL2867245T3 (https=)
PT (1) PT2867245T (https=)
RS (1) RS58005B1 (https=)
SG (2) SG10201703489VA (https=)
SI (1) SI2867245T1 (https=)
SM (1) SMT201800612T1 (https=)
TR (1) TR201815811T4 (https=)
TW (2) TWI587869B (https=)
UA (2) UA129561C2 (https=)
WO (1) WO2014005014A2 (https=)
ZA (2) ZA201409397B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
SG11201901495YA (en) 2016-08-25 2019-03-28 Jcr Pharmaceuticals Co Ltd Method for producing antibody fusion protein
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
US20220002688A1 (en) * 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
JP2022523063A (ja) * 2019-01-30 2022-04-21 アムジエン・インコーポレーテツド アフリベルセプトの属性、並びにその特性決定及び修飾方法
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
EP4232150A4 (en) * 2020-10-23 2025-01-01 Alexion Pharmaceuticals, Inc. METHOD FOR CONTROLLING TOTAL TIALIC ACID CONTENT DURING THE PRODUCTION OF ALKALINE PHOSPHATASE
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US6506598B1 (en) 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
EP1713904B1 (en) 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
CA2711590C (en) * 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
AU2011270672B2 (en) * 2010-06-25 2017-01-12 Shire Human Genetic Therapies, Inc. Treatment of Sanfilippo Syndrome type B
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
JP5865839B2 (ja) * 2010-09-28 2016-02-17 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Similar Documents

Publication Publication Date Title
JP2015523072A5 (https=)
AR091647A1 (es) Purificacion de iduronato-2-sulfatasa
TR201900128T4 (tr) Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller.
HRP20160490T4 (hr) Pripravak i oblik koji sadrže rekombinantnu humanu iduronat-2-sulfatazu te postupci njihove pripreme
BR112013017884A2 (pt) varredura de microcolônia encapsulada com gel
HRP20220455T1 (hr) Modificirane aminokiseline koje sadrže azid grupu
BR112012033703A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
HRP20190982T1 (hr) Peptidi i njihova uporaba
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
WO2010108153A3 (en) Carrier immunoglobulins and uses thereof
WO2010057203A3 (en) Hdl particles for delivery of nucleic acids
DK2343320T3 (da) Anti-gitr-antistoffer og anvendelser deraf
BR112013010522A2 (pt) método para purificação de fator estimulador de colônias de granulócitos humano a partir recombinantes de e. coli
HK1206762A1 (en) Nutritive fragments and proteins with low or no phenylalanine and methods
WO2011097381A3 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
BR112015009201A2 (pt) composição compreendeendo um polipeptídeo recombinante, ácido nucleico codificando o mesmo, célula hospedeira, bem como métodos para produzir uma beta-glucosidase e para hidrolisar um substrato de biomassa lignocelulósica
RU2015112625A (ru) Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция
RU2008100847A (ru) Очищенный компонент сине-зеленых водорослей и способ использования
HRP20171694T1 (hr) Novi pripravci i postupci
BR112015013387B8 (pt) Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas
JP2014510101A5 (https=)
BR112014003841A2 (pt) estratégia de múltiplas cópias para produção em alto título e alta pureza de proteínas de múltiplas subunidades tal como anticorpos em micróbios transformados tal como pichia pastoris
BR112014011664A2 (pt) mutantes de hidantoínase
EP3263123A3 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same